Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or is stage IV and has a change in at least 1 of these genes: ALK, EGFR, HER2 (ERBB2), MET, NTRK, RET, and ROS1. This type of gene change is called an actionable genomic alteration (AGA), which means certain treatments can target the change to fight the cancer. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a toxic drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them. Ivonescimab is a bispecific antibody that can bind to two different antigens at the same time. It binds to programmed cell death protein 1 (PD1), a protein found on the surface of T cells (a type of white blood cell) and vascular endothelial growth factor (VEGF), a protein found on the surface of tumor cells. Ivonescimab may strengthen the immune system and interfere with the ability of tumor cells to grow and spread. Giving a combination of sacituzumab govitecan and ivonescimab work better than either drug alone, and sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan and ivonescimab together may work better than standard treatments at shrinking NSCLC with an AGA.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Posiadanie raka płuc (NSCLC) z potwierdzonym zmiennym genetycznym (mutacją) w jednym z genów: ALK, EGFR, HER2, MET, NTRK, RET lub ROS1
- •Rak, który powrócił po leczeniu lub jest w stadium IV (zaawansowany)
- •Wymiernie duży guz widoczny w tomografii lub rezonansie magnetycznym (badana nie więcej niż 28 dni przed włączeniem)
- •Badanie tomograficzne mózgu w ciągu 42 dni przed włączeniem do badania
- •Jeśli pacjent ma przerzuty do mózgu lub ucisku na rdzeń kręgowy, muszą być one leczone i ustabilizowane
- •Pacjent musi być włączony do badania przez centrum onkologiczne (SWOG)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (41)
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, United States
Palo Alto Medical Foundation Health Care
Palo Alto, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Northeast Georgia Medical Center-Gainesville
Gainesville, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Illinois CancerCare-Bloomington
Bloomington, United States
Illinois CancerCare-Canton
Canton, United States
Illinois CancerCare-Carthage
Carthage, United States
Cancer Care Specialists of Illinois - Decatur
Decatur, United States
Decatur Memorial Hospital
Decatur, United States
Illinois CancerCare-Eureka
Eureka, United States
Illinois CancerCare-Galesburg
Galesburg, United States
Illinois CancerCare-Kewanee Clinic
Kewanee, United States
Illinois CancerCare-Macomb
Macomb, United States
Illinois CancerCare-Ottawa Clinic
Ottawa, United States
Illinois CancerCare-Pekin
Pekin, United States
Illinois CancerCare-Peoria
Peoria, United States
Illinois CancerCare-Peru
Peru, United States
Illinois CancerCare-Princeton
Princeton, United States
Southern Illinois University School of Medicine
Springfield, United States
Springfield Clinic
Springfield, United States
Springfield Memorial Hospital
Springfield, United States
Illinois CancerCare - Washington
Washington, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, United States
University of Michigan Health - Sparrow Lansing
Lansing, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, United States
Saint Francis Medical Center
Cape Girardeau, United States
Billings Clinic Cancer Center
Billings, United States
Community Medical Center
Missoula, United States
New Hampshire Oncology Hematology PA-Concord
Concord, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, United States
Solinsky Center for Cancer Care
Manchester, United States
ProMedica Flower Hospital
Sylvania, United States
Dartmouth Cancer Center - North
Saint Johnsbury, United States
Gundersen Lutheran Medical Center
La Crosse, United States
Trial contact
Site Public Contact
Ari D. Baron
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jonathan W. Riess
PRINCIPAL_INVESTIGATOR
Site Public Contact
Charles H. Nash
PRINCIPAL_INVESTIGATOR
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bryan A. Faller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Christopher M. Reynolds
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Michael S. Buff
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alexander D. Fuld
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Ahmed G. Elsayed
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Kurt Oettel
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.